0001179110-16-024969.txt : 20160518 0001179110-16-024969.hdr.sgml : 20160518 20160518081726 ACCESSION NUMBER: 0001179110-16-024969 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160516 FILED AS OF DATE: 20160518 DATE AS OF CHANGE: 20160518 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OvaScience, Inc. CENTRAL INDEX KEY: 0001544227 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 451472564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9 FOURTH AVE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-500-2802 MAIL ADDRESS: STREET 1: 9 FOURTH AVE CITY: WALTHAM STATE: MA ZIP: 02451 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dipp Michelle CENTRAL INDEX KEY: 0001551614 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35890 FILM NUMBER: 161659473 MAIL ADDRESS: STREET 1: C/O OVASCIENCE, INC. STREET 2: 41 LINSKEY WAY, LEVEL B CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 edgar.xml FORM 4 - X0306 4 2016-05-16 0 0001544227 OvaScience, Inc. OVAS 0001551614 Dipp Michelle C/O OVASCIENCE, INC. 9 FOURTH AVE. WALTHAM MA 02451 1 1 0 0 Chief Executive Officer Common Stock 2016-05-16 4 P 0 20000 7.69 A 497056 I By Longwood Fund III LP Common Stock 2016-05-17 4 P 0 20000 7.56 A 517056 I By Longwood Fund III LP Common Stock 971921 D This Form 4 reflects the purchase of an aggregate of 40,000 shares by the Longwood Fund III LP in the market. The securities in this line are held directly by Longwood Fund III LP. Longwood Fund III GP, LLC is the general partner of Longwood Fund III LP. Voting and investment power with respect to the shares held by Longwood Fund III LP are vested in Richard Aldrich, Michelle Dipp, M.D., Ph.D. and Christoph Westphal, M.D., Ph.D. (collectively, the "Managers"), the managers of Longwood Fund III GP, LLC. Each of the Managers disclaims beneficial ownership of the shares held by Longwood Fund III LP, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in the report shall not be deemed an admission of beneficial ownership of the shares for the purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.80, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.35 to $7.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote. /s/ William C. Hicks, Attorney-in-Fact 2016-05-18